Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancer|October 16, 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles, James E Herndon, Eric J Small, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2012
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerNadeem A Sheikh, Daniel Petrylak, Philip W Kantoff, et al.
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Clinical Genitourinary Cancer|November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaYung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
The Lancet. Oncology|June 8, 2013
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialIan F Tannock, Karim Fizazi, Sergey Ivanov, et al.
European Urology Oncology|May 14, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Pageof 3